An inflammation at systemic and local intraperitoneal levels commonly affects peritoneal dialysis (PD) patients. Now inflammatory markers are recognized as predictors of poor clinical outcomes as they target therapeutic intervention. This article describes the clinical prevalence of inflammation in PD patients along with the causative factors of inflammation. Peritoneal dialysis (PD) is a form of home-based renal replacement therapy for patients with end-stage kidney disease (ESKD) that uses a patient’s peritoneum as a dialysis membrane.
The outcome of PD patients is poor as cardiovascular events (CVE) continue to be the leading cause of death in PD patients. Currently, there is no clear evidence to suggest any significant difference in the systemic inflammatory burden based on the type of dialysis modality received. Defining inflammation and its prevalence Inflammation is a…
